SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Ethics Statement and Study Population
2.2. SP142 PD-L1 Assay and TIL Score
2.3. Atezolizumab and Nab-Paclitaxel Treatments
2.4. Statistical Analyses
3. Results
3.1. Study Population
3.2. Increased Rate of PD-L1 Positivity in Patients with Multiple PD-L1 Tests
3.3. Factors Associated with the Conversion of PD-L1 Status from Negative to Positive According to Sample Type
3.4. Changes in TIL and PD-L1 Scores between Paired Biopsied and Surgical Samples
3.5. Multiple PD-L1 Tests in Patients Treated with Atezolizumab
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 2018, 379, 2108–2121. [Google Scholar] [CrossRef] [PubMed]
- Cortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020, 396, 1817–1828. [Google Scholar] [CrossRef]
- Cortés, J.; Cescon, D.W.; Rugo, H.S.; Im, S.A.; Md Yusof, M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Perez-Garcia, J.; Iwata, H.; et al. Lba16 keynote-355: Final results from a randomized, double-blind phase iii study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic tnbc. Ann. Oncol. 2021, 32, S1289–S1290. [Google Scholar] [CrossRef]
- Mittendorf, E.A.; Zhang, H.; Barrios, C.H.; Saji, S.; Jung, K.H.; Hegg, R.; Koehler, A.; Sohn, J.; Iwata, H.; Telli, M.L.; et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (impassion031): A randomised, double-blind, phase 3 trial. Lancet 2020, 396, 1090–1100. [Google Scholar] [CrossRef]
- Gianni, L.; Huang, C.S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Bianchini, G.; Russo, S.; et al. Pathologic complete response (pcr) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: Neotrip michelangelo randomized study. Ann. Oncol. 2022, 33, 534–543. [Google Scholar] [CrossRef]
- Emens, L.A.; Adams, S.; Barrios, C.H.; Diéras, V.; Iwata, H.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Winer, E.P.; Patel, S.; et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: Impassion130 final overall survival analysis. Ann. Oncol. 2021, 32, 983–993. [Google Scholar] [CrossRef]
- Emens, L.A.; Molinero, L.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Diéras, V.; Iwata, H.; Barrios, C.H.; Nechaeva, M.; Nguyen-Duc, A.; et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the impassion130 study. J. Natl. Cancer Inst. 2021, 113, 1005–1016. [Google Scholar] [CrossRef]
- Ahn, S.G.; Kim, S.K.; Shepherd, J.H.; Cha, Y.J.; Bae, S.J.; Kim, C.; Jeong, J.; Perou, C.M. Clinical and genomic assessment of pd-l1 sp142 expression in triple-negative breast cancer. Breast Cancer Res. Treat. 2021, 188, 165–178. [Google Scholar] [CrossRef]
- Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17, 1474–1481. [Google Scholar] [CrossRef]
- Emens, L.A.; Cruz, C.; Eder, J.P.; Braiteh, F.; Chung, C.; Tolaney, S.M.; Kuter, I.; Nanda, R.; Cassier, P.A.; Delord, J.P.; et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol. 2019, 5, 74–82. [Google Scholar] [CrossRef]
- Cha, Y.J.; Ahn, S.G.; Bae, S.J.; Yoon, C.I.; Seo, J.; Jung, W.H.; Son, E.J.; Jeong, J. Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: A retrospective analysis. Breast Cancer Res. Treat. 2018, 171, 295–302. [Google Scholar] [CrossRef] [PubMed]
- Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; Van den Eynden, G.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (tils) in breast cancer: Recommendations by an international tils working group 2014. Ann. Oncol. 2015, 26, 259–271. [Google Scholar] [CrossRef] [PubMed]
- DeLong, E.R.; DeLong, D.M.; Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988, 44, 837–845. [Google Scholar] [CrossRef] [PubMed]
- Sarradin, V.; Lusque, A.; Filleron, T.; Dalenc, F.; Franchet, C. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: The mimosa-1 study. Breast Cancer Res. 2021, 23, 61. [Google Scholar] [CrossRef]
- Shin, J.; Chung, J.H.; Kim, S.H.; Lee, K.S.; Suh, K.J.; Lee, J.Y.; Kim, J.W.; Lee, J.O.; Kim, J.W.; Kim, Y.J.; et al. Effect of platinum-based chemotherapy on pd-l1 expression on tumor cells in non-small cell lung cancer. Cancer Res. Treat. 2019, 51, 1086–1097. [Google Scholar] [CrossRef]
- Zhang, P.; Ma, Y.; Lv, C.; Huang, M.; Li, M.; Dong, B.; Liu, X.; An, G.; Zhang, W.; Zhang, J.; et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 2016, 107, 1563–1571. [Google Scholar] [CrossRef]
- Gniadek, T.J.; Li, Q.K.; Tully, E.; Chatterjee, S.; Nimmagadda, S.; Gabrielson, E. Heterogeneous expression of pd-l1 in pulmonary squamous cell carcinoma and adenocarcinoma: Implications for assessment by small biopsy. Mod. Pathol. 2017, 30, 530–538. [Google Scholar] [CrossRef] [Green Version]
- Ilie, M.; Long-Mira, E.; Bence, C.; Butori, C.; Lassalle, S.; Bouhlel, L.; Fazzalari, L.; Zahaf, K.; Lalvée, S.; Washetine, K.; et al. Comparative study of the pd-l1 status between surgically resected specimens and matched biopsies of nsclc patients reveal major discordances: A potential issue for anti-pd-l1 therapeutic strategies. Ann. Oncol. 2016, 27, 147–153. [Google Scholar] [CrossRef]
- Li, C.; Huang, C.; Mok, T.S.; Zhuang, W.; Xu, H.; Miao, Q.; Fan, X.; Zhu, W.; Huang, Y.; Lin, X.; et al. Comparison of 22c3 pd-l1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. J. Thorac. Oncol. 2017, 12, 1536–1543. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Wu, J.; Deng, J.; She, Y.; Chen, C. The detection value of pd-l1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: A meta-analysis. J. Thorac. Dis. 2021, 13, 4301–4310. [Google Scholar] [CrossRef]
- Mittendorf, E.A.; Philips, A.V.; Meric-Bernstam, F.; Qiao, N.; Wu, Y.; Harrington, S.; Su, X.; Wang, Y.; Gonzalez-Angulo, A.M.; Akcakanat, A.; et al. Pd-l1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014, 2, 361–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stanton, S.E.; Disis, M.L. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J. Immunother. Cancer 2016, 4, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szekely, B.; Bossuyt, V.; Li, X.; Wali, V.B.; Patwardhan, G.A.; Frederick, C.; Silber, A.; Park, T.; Harigopal, M.; Pelekanou, V.; et al. Immunological differences between primary and metastatic breast cancer. Ann. Oncol. 2018, 29, 2232–2239. [Google Scholar] [CrossRef]
- Park, I.H.; Kim, G.M.; Kim, J.H.; Kim, H.; Park, K.H.; Park, Y.H.; Baek, S.K.; Sim, S.H.; Ahn, H.K.; Lee, G.-W.; et al. Randomized, phase ii trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (tnbc) with residual invasive cancer after neoadjuvant chemotherapy (mirinae trial, kcsg-br18-21). J. Clin. Oncol. 2020, 38, TPS597. [Google Scholar]
- Pusztai, L.; Barlow, W.; Ganz, P.; Henry, N.; White, J.; Jagsi, R.; Mammen, J.; Lew, D.; Mejia, J.; Karantza, V.; et al. Abstract ot1-02-04: Swog s1418/nrg-br006: A randomized, phase iii trial to evaluate the efficacy and safety of mk-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes (>pn1mic) after neoadjuvant chemotherapy. Cancer Res. 2018, 78, OT1-02-04. [Google Scholar]
- Rugo, H.S.; Loi, S.; Adams, S.; Schmid, P.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Winer, E.P.; Kockx, M.M.; et al. Pd-l1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J. Natl. Cancer Inst. 2021, 113, 1733–1743. [Google Scholar] [CrossRef]
- Ahn, S.; Woo, J.W.; Kim, H.; Cho, E.Y.; Kim, A.; Kim, J.Y.; Kim, C.; Lee, H.J.; Lee, J.S.; Bae, Y.K.; et al. Programmed death ligand 1 immunohistochemistry in triple-negative breast cancer: Evaluation of inter-pathologist concordance and inter-assay variability. J. Breast Cancer 2021, 24, 266–279. [Google Scholar] [CrossRef]
Upfront Surgery (n = 47) | Neoadjuvant Chemotherapy (n = 30) | |||||
---|---|---|---|---|---|---|
Biopsied Sample | Surgical Sample | p | Biopsied Sample | Surgical Sample | p | |
PD-L1 status | 0.007 | 0.606 | ||||
Negative | 32 (68%) | 18 (40%) | 16 (53%) | 13 (43%) | ||
Positive | 15 (32%) | 29 (60%) | 14 (47%) | 17 (57%) |
Variable | Odds Ratio | 95% CI | p |
---|---|---|---|
Continuous TIL | 1.11 | 1.04–1.27 | 0.029 |
TIL ≥ 20% | 19.29 | 2.83–393.46 | 0.010 |
Histologic grade at biopsy | 1.143 | 0.279–4.683 | 0.853 |
Clinical T stage | 1.798 | 0.515–6.272 | 0.357 |
Clinical N stage | 1.963 | 0.086–44.976 | 0.673 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baek, S.H.; Kim, J.H.; Bae, S.J.; Ji, J.H.; Lee, Y.; Jeong, J.; Cha, Y.J.; Ahn, S.G. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. Cancers 2022, 14, 3042. https://doi.org/10.3390/cancers14133042
Baek SH, Kim JH, Bae SJ, Ji JH, Lee Y, Jeong J, Cha YJ, Ahn SG. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. Cancers. 2022; 14(13):3042. https://doi.org/10.3390/cancers14133042
Chicago/Turabian StyleBaek, Seung Ho, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, and Sung Gwe Ahn. 2022. "SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer" Cancers 14, no. 13: 3042. https://doi.org/10.3390/cancers14133042